Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Acute Ischemic Stroke

In brief

This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Key facts

Study ID

NCT01098981

Run by

Cerevast Therapeutics, Inc.

People needed

675

Starts

2013-05-01

Expected to finish

2015-04-01

Last updated by the study team

2015-04-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females 18 - 80 years of age
• Subjects presenting within timeframe for intravenous tPA treatment approved by local regulatory authorities but no more than 4.5 hours from onset of symptoms
• No signs of intracranial bleeding on assessment by non-contrast CT
• Subjects with neurological deficits of a total NIHSS score ≥ 10 points
• Subjects that in the opinion of the treating physician require treatment with full dose IV tPA as standard of care per institutional standards
• SBP < 185 mmHg and DBP < 105 mmHg at baseline or after treatment of hypertension with medications prior to tPA bolus
• Pre-morbid modified Rankin score of 0-1
• Provision of informed consent as demonstrated by the subject's signature or by the signature of the subject's authorized legal representative on the Informed Consent Form in accordance with all local and national regulations
• Co-signature on the Informed Consent Form by a qualified member of the study staff signifying that, in his/her professional opinion, informed consent has been obtained in accordance with all local and national regulations
• For subjects in the optional arterial recanalization substudy:
• Occlusion located in the intracranial carotid tee through mid M2 or proximal A2, or intracranial vertebrobasilar or P1/proximal P2 segments or tandem lesions
• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min for patients undergoing CTA or MRA

You may not qualify if…

• Subjects with primary intra-arterial thrombolysis
• Females who are pregnant or breast feeding
• Subjects receiving other investigational drugs, procedures, or therapies within 30 days prior to study treatment
• Subjects with any standard contraindication for intravenous tPA therapy
• Significant concurrent medical/neurological conditions or test values that, in the opinion of the investigator, pose significant risk to the subject and warrant exclusion from the study

Where it is running

• Cerevast Therapeutics, Inc. — Redmond, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.